|
Indian pharma eyes bigger New Zealand market through FTA-driven regulatory reforms
|
|
Nandit Vijayasimha Bengaluru
November 02 , 2026
|
|
|
The proposed India–New Zealand Free Trade Agreement (FTA) which came into effect on October 20, 2026 is expected to create fresh export opportunities for the Indian pharmaceutical industry by improving market access and addressing regulatory barriers of generic medication, branded formulations and medical devices.
Anurag Kumar, chairman & managing director, Biodeal Pharmaceuticals, said that for India's pharmaceutical industry, the value of a trade agreement lies not simply in the market access it creates, but in the ability of manufacturers to translate that access into sustainable business. The India–New Zealand FTA presents to explore new export relationships. Realising this potential, however, will require a clear understanding of market requirements, stronger commercial partnerships and manufacturing capabilities aligned with international expectations.
Exporters should identify products with a competitive advantage, assess demand and registration requirements, and evaluate the commercial viability of entering the market before committing resources, he added.
For Indian contract development and manufacturing organisations (CDMOs), the opportunity extends beyond production volumes. International customers seek technical expertise, consistent quality, dependable supply and flexibility to meet evolving product requirements.
Meeting these expectations requires robust quality systems, process validation, technical documentation and compliance with destination-market regulations. These capabilities are essential to building customer confidence and long-term partnerships. Our focus on quality and regulatory compliance is reflected in our WHO-GMP, PIC/S and Health Canada certifications. Our capabilities in nasal sprays and dry powder inhalers (DPIs), alongside continued innovation in these segments, represent specialised areas of pharmaceutical manufacturing that can support partnerships aligned with our technical expertise, Kumar told Pharmabiz.
Manufacturing readiness alone does not guarantee export success. Companies must assess distribution networks, logistics, pricing, working capital and local purchasing practices.
For New Zealand, this preparation should include five practical priorities.
First is to verify eligibility under the FTA's rules of origin. There is a need for companies to check each product's Harmonised System (HS) classification, applicable tariff schedule and product-specific origin criteria. Maintain manufacturing and sourcing records and coordinate with the New Zealand importer to establish eligibility for preferential duties rather than assuming all Indian pharmaceutical exports qualify.
Second is to conduct a Medsafe dossier gap analysis, compare existing product dossiers, including filings prepared for PIC/S-aligned markets, against the requirements applicable to the proposed New Zealand registration pathway. Identify gaps in quality documentation, stability data, bioequivalence evidence where applicable and labelling, then prioritise products requiring the least additional regulatory work.
Third is to assess existing GMP and GCP inspection reports to confirm scope and acceptance requirements with the relevant New Zealand authority. Fourth is to appoint an eligible New Zealand-based sponsor and clearly allocate responsibilities for regulatory submissions, safety reporting and product-related obligations. Fifth is to Align with PHARMAC's funding and tender process.
For smaller manufacturers, a phased approach built around a focused product portfolio and realistic demand assessment can help manage risk and establish sustainable commercial relationships, he said.
Nevertheless, the India–New Zealand FTA provides a platform for Indian pharmaceutical companies to explore international collaboration. Its commercial impact will depend on how effectively businesses combine manufacturing strength, regulatory preparedness and reliable execution. Our industry has an established foundation in quality manufacturing and global supply. By building on specialised capabilities, targeted market development and partnerships that deliver long-term value, exporters and CDMOs can turn improved trade access into sustainable export growth, said Kumar.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|